{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T22:48:50Z","timestamp":1789858130837,"version":"4.0.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1136\/ard.2007.069484","type":"journal-article","created":{"date-parts":[[2007,11,3]],"date-time":"2007-11-03T00:34:45Z","timestamp":1194050085000},"page":"1145-1152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"title":["Focus on adverse events of tumour necrosis factor \u00ce\u00b1 blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients"],"prefix":"10.1016","volume":"67","author":[{"given":"V","family":"Gerloni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Pontikaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Gattinara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Fantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2007.069484_bib1","first-page":"1991","article-title":"Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997.","volume":"25","author":"Petty","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.069484_bib2","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.069484_bib3","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1056\/NEJM198605153142001","article-title":"Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis: results of the USA\u00e2\u20ac\u201cUSSR double-blind placebo-controlled trial.","volume":"314","author":"Brewer","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2007.069484_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/art.1780310103","article-title":"Characteristics of responders and non responders to slow-acting antirheumatic drugs in juvenile rheumatoid arthritis.","volume":"31","author":"Giannini","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.069484_bib5","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/art.1780330402","article-title":"Auranofin in the treatment of juvenile rheumatoid arthritis: results of the USA\u00e2\u20ac\u201cUSSR double-blind, placebo-controlled trial.","volume":"33","author":"Giannini","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.069484_bib6","first-page":"2353","article-title":"Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial.","volume":"21","author":"Silverman","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.069484_bib7","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1056\/NEJM199204163261602","article-title":"MTX in resistant juvenile rheumatoid arthritis: results of the USA\u00e2\u20ac\u201cUSSR double-blind, placebo-controlled trial.","volume":"326","author":"Giannini","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2007.069484_bib8","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/1529-0131(199805)41:5<808::AID-ART6>3.0.CO;2-T","article-title":"Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study.","volume":"41","author":"van Rossum","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.069484_bib9","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/rheumatology\/40.8.907","article-title":"Efficacy and safety profile of cyclosporine A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a ten-year prospective study.","volume":"40","author":"Gerloni","year":"2001","journal-title":"Rheumatology"},{"key":"10.1136\/ard.2007.069484_bib10","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/rheumatology\/38.8.737","article-title":"Autologous stem cell transplantation: an alternative for refractory juvenile chronic arthritis.","volume":"38","author":"Kuis","year":"1999","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2007.069484_bib11","first-page":"394","article-title":"Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis.","volume":"30","author":"Bowyer","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.069484_bib12","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis.","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2007.069484_bib13","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/art.10710","article-title":"Long-term efficacy and safety of etanercept in children with polyarticular course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial.","volume":"48","author":"Lovell","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.069484_bib14","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/art.20793","article-title":"Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study.","volume":"52","author":"Gerloni","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.069484_bib15","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","article-title":"A randomized, placebo controlled trial of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis.","volume":"56","author":"Ruperto","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1136\/ard.2007.069484_bib16","first-page":"56","article-title":"48-week data from the study of Adalimumab in children with juvenile rheumatoid arthritis (JRA).","volume":"65","author":"Ruperto","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.069484_bib17","first-page":"1677","article-title":"Safety and efficacy of high dose etanercept in treatment of juvenile rheumatoid arthritis.","volume":"28","author":"Takei","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.069484_bib18","first-page":"867","article-title":"Good results from combining etanercept to prevailing DMARD therapy in refractory juvenile idiopathic arthritis.","volume":"20","author":"Haapasaari","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2007.069484_bib19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1136\/ard.62.3.245","article-title":"Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study.","volume":"62","author":"Lahdenne","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.069484_bib20","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1136\/ard.60.4.410","article-title":"A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot study.","volume":"60","author":"Schmeling","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.069484_bib21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/ard.61.2.171","article-title":"Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period.","volume":"61","author":"Kietz","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.069484_bib22","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/art.10885","article-title":"Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.","volume":"48","author":"Quartier","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.069484_bib23","first-page":"723","article-title":"Etanercept in systemic juvenile idiopathic arthritis.","volume":"20","author":"Russo","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2007.069484_bib24","first-page":"2055","article-title":"Prolonged efficacy of etanercept in refractory enthesitis-related arthritis.","volume":"31","author":"Henrickson","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.069484_bib25","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1002\/art.21121","article-title":"Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy.","volume":"52","author":"Tse","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.069484_bib26","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1136\/ard.2003.014886","article-title":"Paediatric Rheumatology Collaborative Group. The German etanercept registry for treatment of juvenile idiopathic arthritis.","volume":"63","author":"Horneff","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 82","key":"10.1136\/ard.2007.069484_bib27","article-title":"Preliminary evidence that etanercept is more effective than metothrexate in suppressing inflammation and in reducing radiographic progression in JIA. ACR Congress 2005.","volume":"52","author":"Nielsen","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1136\/ard.2007.069484_bib28","first-page":"253","article-title":"A phase 4 registry of etanercept in children with juvenile rheumatoid arthritis","volume":"65","author":"Giannini","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1136\/ard.2007.069484_bib29","first-page":"572","article-title":"Long term follow-up of etanercept in the treatment of juvenile idiopathic arthritis; the Dutch national study.","volume":"65","author":"Twilt","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1136\/ard.2007.069484_bib30","first-page":"440","article-title":"Etanercept in patients with juvenile idiopathic arthritis: results of a retrospective multicenter registry.","volume":"65","author":"Calvo","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.069484_bib31","first-page":"252","article-title":"Safety of anti-TNFalpha therapy in children with juvenile idiopathic arthritis.","volume":"22","author":"Dekker","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2007.069484_bib32","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.semarthrit.2004.11.006","article-title":"Consensus Development Conference. The benefit\/risk profile of TNF-blocking agents: findings of a consensus panel.","volume":"34","author":"Hochberg","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard.2007.069484_bib33","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/art.21885","article-title":"Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.","volume":"54","author":"Lovell","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.069484_bib34","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and MTX in the treatment of rheumatoid arthritis.","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2007.069484_bib35","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2165\/00003495-200059060-00010","article-title":"Infliximab: a review of its use in the management of rheumatoid arthritis.","volume":"59","author":"Markham","year":"2000","journal-title":"Drugs"},{"issue":"2","key":"10.1136\/ard.2007.069484_bib36","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/00019053-200422001-00005","article-title":"Drugs that block tumor necrosis factor: experience in patients with rheumatoid arthritis.","volume":"22","author":"Moreland","year":"2004","journal-title":"Pharmacoeconomics"},{"key":"10.1136\/ard.2007.069484_bib37","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/01.MIB.0000158166.88238.ea","article-title":"Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium.","volume":"11","author":"Jacobstein","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"10.1136\/ard.2007.069484_bib38","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor \u00ce\u00b1 monoclonal antibody combined with low-dose weekly MTX in rheumatoid arthritis.","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.069484_bib39","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/00004836-200302000-00024","article-title":"Red man syndrome and infliximab.","volume":"36","author":"Lobel","year":"2003","journal-title":"J Clin Gastroenterol"},{"key":"10.1136\/ard.2007.069484_bib40","first-page":"2529","article-title":"Niacin-like reaction to infliximab infusion in systemic juvenile rheumatoid arthritis.","volume":"31","author":"Becker","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.069484_bib41","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jaapos.2005.12.002","article-title":"Optic neuritis associated with etanercept therapy for juvenile arthritis.","volume":"10","author":"Tauber","year":"2006","journal-title":"J AAPOS"},{"key":"10.1136\/ard.2007.069484_bib42","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/01.md.0000180044.19285.9a","article-title":"Infections associated with tumor necrosis factor-alpha antagonists.","volume":"84","author":"Crum","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1136\/ard.2007.069484_bib43","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/rheumatology\/keh074","article-title":"Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis.","volume":"43","author":"Armbrust","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2007.069484_bib44","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1056\/NEJM200202213460815","article-title":"Tuberculosis and treatment with infliximab.","volume":"346","author":"Myers","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2007.069484_bib45","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/01.inf.0000055092.90609.e5","article-title":"Multifocal septic arthritis and osteomyelitis caused by group A Streptococcus in a patient receiving immunomodulating therapy with etanercept.","volume":"22","author":"Elwood","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1136\/ard.2007.069484_bib46","first-page":"401","article-title":"Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis.","volume":"30","author":"Ramanan","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.069484_bib47","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/art.21190","article-title":"Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.","volume":"52","author":"De Rycke","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.069484_bib48","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1002\/1529-0131(200011)43:11<2606::AID-ANR31>3.0.CO;2-X","article-title":"Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis.","volume":"43","author":"Bloom","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.069484_bib49","first-page":"276","article-title":"Drug-induced systemic lupus erythematosus associated with etanercept therapy in a child with juvenile idiopathic arthritis.","volume":"21","author":"Lepore","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2007.069484_bib50","first-page":"740","article-title":"Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept.","volume":"32","author":"Mor","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.069484_bib51","first-page":"203","article-title":"Development of Crohn disease during anti-TNF-alpha therapy in a child with juvenile idiopatic arthritis.","volume":"39","author":"Ruemelle","year":"2004","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1136\/ard.2007.069484_bib52","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/rheumatology\/keh658","article-title":"Etanercept and uveitis in patients with juvenile idiopathic arthritis.","volume":"44","author":"Schmeling","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2007.069484_bib53","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/art.20904","article-title":"A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis.","volume":"53","author":"Smith","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.069484_bib54","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s00296-003-0308-1","article-title":"Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis.","volume":"23","author":"Mangge","year":"2003","journal-title":"Rheumatol Int"},{"key":"10.1136\/ard.2007.069484_bib55","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ophtha.2005.09.037","article-title":"Retrospective case review of pediatric patients with uveitis treated with infliximab.","volume":"113","author":"Rajaraman","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1136\/ard.2007.069484_bib56","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/rheumatology\/kel030","article-title":"Tumour necrosis factor-\u00ce\u00b1 inhibitors in the treatment of childhood uveitis.","volume":"45","author":"Saurenmann","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2007.069484_bib57","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jpeds.2006.08.044","article-title":"Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents.","volume":"149","author":"Saurenmann","year":"2006","journal-title":"J Pediatr"},{"key":"10.1136\/ard.2007.069484_bib58","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1442-9071.2005.01062.x","article-title":"Infliximab for juvenile idiopathic arthritis-associated uveitis.","volume":"33","author":"Richards","year":"2005","journal-title":"Clin Experiment Ophthalmol"},{"key":"10.1136\/ard.2007.069484_bib59","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ophtha.2006.01.005","article-title":"Favorable response to high-dose infliximab for refractory childhood uveitis.","volume":"113","author":"Kahn","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1136\/ard.2007.069484_bib60","first-page":"1146","article-title":"Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.","volume":"34","author":"Foeldvari","year":"2007","journal-title":"J Rheumatol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724386376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724386376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2007.069484","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T04:56:17Z","timestamp":1737262577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724386376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":60,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["S0003496724386376"],"URL":"https:\/\/doi.org\/10.1136\/ard.2007.069484","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2008,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Focus on adverse events of tumour necrosis factor \u00ce\u00b1 blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2007.069484","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 2008 Published by Elsevier Inc. Publishing Group and European League Against Rheumatism. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}